AQUILO CAPITAL MANAGEMENT LLC
Q4 2020 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001591986
· CRD 153022
· SEC-registered investment adviser
$481.2M Reported Value Total
AQUILO CAPITAL MANAGEMENT, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $598,727,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
3 funds
· $277.1M gross asset value
Hedge Fund: $189.4M · Other: $87.6M
Source: Form ADV filed 2024-03-26
Reported value
$481.2M
Quarter over quarter
+44.4%
Holdings
15
Top-10 concentration
88.9%
Key People
Form ADV owners & control persons
Marc Robert Schneidman
MANAGER
Adam Scott Bristol
MANAGING DIRECTOR - HEAD OF INVESTMENTS
Tony Michael Berta
CFO AND CCO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2020 13F record
Q4 2020 13F filing summary
| Period of report | December 31, 2020 |
|---|---|
| Filed | February 16, 2021 |
| Form | 13F-HR |
| Reported value | $481.2M |
| Positions | 15 |
| Change in reported value | -49.1% |
| New positions | 2 |
| Exited positions | 2 |
| Position turnover | 23.5% |
| Top-10 concentration | 88.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2025 13F
Filed May 15, 2025
|
12 | $55.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
13 | $66.3M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
13 | $131.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $103.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
10 | $133.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
9 | $160.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
12 | $110.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
12 | $180.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
11 | $241.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
12 | $266.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $277.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
12 | $293.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
12 | $680.4M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
13 | $881.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
13 | $550.6M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
15 | $384.9M |
|
Q1 2021 13F
Filed May 17, 2021
|
15 | $553.4M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
15 | $481.2M |
|
Q3 2020 13F
Filed Nov 16, 2020
|
15 | $944.6M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
13 | $495.9M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 17 holdings · Q4 2020
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SPRO SPERO THERAPEUTICS INC | $76.2M | 15.85% |
| 2 | IBB P ISHARES TR | $75.7M | 15.73% |
| 3 | XBI P SPDR SER TR | $70.4M | 14.63% |
| 4 | BPMC BLUEPRINT MEDICINES CORP | $42.6M | 8.86% |
| 5 | NGM NGM BIOPHARMACEUTICALS INC | $30.5M | 6.33% |
| 6 | DRNA DICERNA PHARMACEUTICALS INC | $29.9M | 6.21% |
| 7 | ARWR ARROWHEAD PHARMACEUTICALS IN | $28.1M | 5.84% |
| 8 | ANAB ANAPTYSBIO INC | $26.1M | 5.43% |
| 9 | QURE UNIQURE NV | $25.4M | 5.27% |
| 10 | RGNX REGENXBIO INC | $22.8M | 4.75% |
| 11 | DNTH MAGENTA THERAPEUTICS INC | $17.8M | 3.69% |
| 12 | AMYT AMRYT PHARMA PLC | $11.3M | 2.35% |
| 13 | PIRS PIERIS PHARMACEUTICALS INC | $9.2M | 1.91% |
| 14 | LKFT GALAPAGOS NV | $6.9M | 1.44% |
| 15 | ARGX ARGENX SE | $3.7M | 0.78% |
| 16 | GMAB GENMAB A/S | $3.7M | 0.76% |
| 17 | FDMT 4D MOLECULAR THERAPEUTICS IN | $829.0K | 0.17% |
Values as reported on the Q4 2020 Form 13F. Every position is in the holdings table below.